Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
5.79
-0.20 (-3.34%)
At close: Apr 1, 2025, 4:00 PM
5.97
+0.18 (3.19%)
After-hours: Apr 1, 2025, 6:00 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
205
Market Cap
640.02M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
COGT News
- 7 days ago - Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 25 days ago - Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - GlobeNewsWire
- 5 weeks ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha
- 2 months ago - Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data - Seeking Alpha
- 4 months ago - Why Is Cogent Biosciences Stock Trading Higher On Monday? - Benzinga